Selvam R Sendhil
ORCID:0000-0001-8010-4296
发表论文 17 篇 · 总被引 118 次 · h-index 6
代表论文
- Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis (2022 · Leukemia · 被引 49)
- Burden of Herpes Zoster Among Patients with Psoriasis in the United States (2023 · Dermatology and Therapy · 被引 15)
- Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma (2022 · The Oncologist · 被引 12)
- Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States (2021 · Journal of Managed Care & Specialty Pharmacy · 被引 10)
- Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States (2025 · JBMR Plus · 被引 8)
- PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC) (2021 · Value in Health · 被引 6)